Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
about
Current targeted therapies in the treatment of advanced colorectal cancer: a reviewReceptor tyrosine kinase-mediated angiogenesisImproving cancer immunotherapy by targeting the STATe of MDSCsA case of retinal tear associated with use of sorafenib.Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Anti-VEGF Cancer Therapy in Nephrology PracticeSmall-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesAn open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Rapid optimization of drug combinations for the optimal angiostatic treatment of cancerConcise drug review: pazopanib and axitinib.Experience with sunitinib in the treatment of metastatic renal cell carcinomaDW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitroA human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugsAnti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?Antiangiogenic activity and pharmacogenomics of medicinal plants from traditional korean medicine.Controlling escape from angiogenesis inhibitors.Progress and contrasts of the development of tivozanib for therapy of kidney cancer.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.Clinical pharmacology of axitinib.Targeted therapy of kidney cancer: keeping the art around the algorithms.Axitinib for the treatment of advanced renal cell carcinoma.Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.Overview of fundamental study of pazopanib in cancer.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.Novel pyrazole and indazole derivatives: synthesis and evaluation of their anti-proliferative and anti-angiogenic activities.Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review.Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes.Individualized dosing with axitinib: rationale and practical guidance.Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
P2860
Q26740067-334BCE84-E0C3-4450-92DC-CFE5B430DB15Q27001612-EA92D59A-0996-4414-8365-2E86BDCD85E0Q28066797-04D9D5D9-677B-4415-A01D-021F36C3D4B4Q30411375-295B128F-E1B6-4B74-8CF7-7378575EAE4CQ33408127-4218B8A8-2027-4B1A-99D6-CD6CAAB0F23FQ34077272-E8E0C67D-3D54-4FA0-83B0-EEDA28866D8CQ34094154-C01A3F3A-F77B-4C3C-AADE-F7623980B7D4Q34152125-748C7051-89E4-4D99-8919-5310580DD3EAQ34158454-F2CE6064-5C10-4C3E-A8DC-B86392D6032AQ34484368-39BA2F7D-0241-47C8-9121-1AED4D6A0ADAQ35001062-5D81271C-8FB8-4BCB-A732-06F0A6AE7734Q35534962-A38727D6-5DB1-4AAF-898A-9F902C4D53BCQ35757208-A1BF5F6C-262C-4343-B289-A4E34092D1D6Q36182836-CD5858F4-4D5A-48FF-B24D-F01DFBECDA8DQ36231729-11AF2D89-A9EE-4BB1-8DBE-DB69F7B30B85Q36644256-95778D49-8F28-486A-BB5A-F2D9D1298BA9Q36746141-999A33D0-2EAB-47FE-AF61-5FA4BD02FE92Q36897996-91198290-ACD4-4AD2-B3EE-3C86E0355D26Q36936900-E411E53A-4DA4-4DDC-A802-2DB50F2F0006Q37077910-4C37F708-9E68-4F47-912D-E970D9E24A85Q37672654-267FCAFD-9E7A-4787-97B9-96CB822D8E6CQ37958038-5E7EEE55-48A3-42B3-956A-8D013BA8D661Q37976467-70298FC8-6C57-44CB-B5DA-691FA28618A0Q38015387-DB105104-5FE7-4E92-860F-43CB80811500Q38107175-DB13270D-40FA-486E-8B2C-3E6A784FDFC8Q38118060-B46729C1-D81A-418D-9FA2-83791E94464EQ38170397-501EDD55-43A2-4A91-B195-C92F65465F3BQ38261099-9FA8CEFC-F0B9-492C-A7AE-D25581AD1D37Q38645097-65CC5441-3021-4593-B4FD-470B796F2E95Q38653213-9020B43A-008D-48D7-BE13-1AEA8CF2993DQ38696525-9DB28B09-45DD-417C-A2B8-5A8291BD4C33Q38720430-836D642F-24C8-4F3B-A2E2-D940AE09D30AQ39056231-2058DAB6-8CC1-4567-A4EB-D286BBDB7D79Q39329621-38BA6370-7B96-4EB1-A7F3-BEA83424173AQ41712860-04A5EB14-A834-43D3-8D8F-E76B0C1A9D02Q42402968-CE07FEFA-6487-4FE7-AB9F-C8BA656CAB20Q47156330-D87554CC-9081-4416-8A10-840F2E6DCBDFQ47156365-A37399AE-BDD7-406F-9CBE-AE0E8381C769Q47271327-F5330395-0290-41AC-95EF-327E8D196474Q53111652-0B94047B-2270-4B51-BF17-1E41C42BADDB
P2860
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@ast
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@en
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@nl
type
label
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@ast
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@en
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@nl
prefLabel
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@ast
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@en
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
@nl
P2860
P921
P1476
Development of second-generation VEGFR tyrosine kinase inhibitors: current status
@en
P2093
Pankaj Bhargava
P2860
P2888
P304
P356
10.1007/S11912-011-0154-3
P577
2011-04-01T00:00:00Z
P5875
P6179
1021361914